Jason Zemansky

Stock Analyst at B of A Securities

(1.13)
# 2149
Out of 5,441 analysts
46
Total ratings
Success rate
Average return
14 Stocks
Name Action PT Current % Upside Ratings Updated
INSM Insmed
Maintains: Strong Buy
94 109
112.87 -3.43% 10 Jun 11, 2025
KROS Keros Therapeutics
Downgrades: Neutral
32 18
13.35 34.83% 2 Jun 10, 2025
RCKT Rocket Pharmaceutica...
Maintains: Buy
32 9
2.93 207.17% 1 May 28, 2025
CYTK Cytokinetics
Maintains: Neutral
62 54
33.2 62.65% 4 Apr 15, 2025
TVTX Travere Therapeutics
Maintains: Strong Buy
29 31
17.29 79.29% 4 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
22 17
9.17 85.39% 5 Feb 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 29
5.54 423.47% 2 Nov 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
30 31
12.5 148% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
3 3
1.85 35.14% 5 Jun 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
391 23
9.81 134.45% 2 Dec 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
230
18.2 1163.74% 1 Jul 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
9 10
1.18 747.46% 4 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
450 162
0.93 17319.35% 1 Feb 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
145 155
n/a n/a 2 Dec 13, 2021